| Secondary |
| Ischaemia |
25.6% |
| B Precursor Type Acute Leukaemia |
22.0% |
| Alpha Haemolytic Streptococcal Infection |
7.3% |
| Candidiasis |
7.3% |
| Staphylococcal Infection |
7.3% |
| Product Used For Unknown Indication |
6.1% |
| Acute Myeloid Leukaemia |
4.9% |
| Asthma |
3.7% |
| Antibiotic Therapy |
2.4% |
| Antifungal Treatment |
2.4% |
| Life Support |
2.4% |
| Systemic Candida |
2.4% |
| Fungal Infection |
1.2% |
| Hepatosplenic Candidiasis |
1.2% |
| Relapsing-remitting Multiple Sclerosis |
1.2% |
| Schizoaffective Disorder |
1.2% |
| Schizophrenia |
1.2% |
|
| Staphylococcal Infection |
21.4% |
| Nervous System Disorder |
14.3% |
| Subclavian Vein Thrombosis |
14.3% |
| Completed Suicide |
7.1% |
| Dental Prosthesis User |
7.1% |
| Granulocytopenia |
7.1% |
| Pneumonia |
7.1% |
| Respiratory Distress |
7.1% |
| Sinoatrial Block |
7.1% |
| Skin Discolouration |
7.1% |
|
| Concomitant |
| Product Used For Unknown Indication |
21.6% |
| Prophylaxis |
7.2% |
| Stem Cell Transplant |
6.6% |
| Antifungal Prophylaxis |
6.4% |
| Prophylaxis Against Graft Versus Host Disease |
6.3% |
| Immunosuppression |
5.9% |
| Myelodysplastic Syndrome |
5.7% |
| Burkitt's Lymphoma |
5.5% |
| Antiviral Prophylaxis |
5.1% |
| Bone Marrow Conditioning Regimen |
4.4% |
| Chronic Graft Versus Host Disease |
4.2% |
| Multiple Myeloma |
4.0% |
| Acute Myeloid Leukaemia |
3.2% |
| Infection Prophylaxis |
3.0% |
| Drug Use For Unknown Indication |
2.3% |
| Atrial Fibrillation |
1.9% |
| Premedication |
1.9% |
| Renal And Pancreas Transplant |
1.9% |
| Non-hodgkin's Lymphoma |
1.7% |
| Plasma Cell Myeloma |
1.3% |
|
| Thrombocytopenia |
21.9% |
| Myelodysplastic Syndrome |
10.9% |
| Chronic Graft Versus Host Disease |
6.3% |
| Infection |
6.3% |
| Renal Impairment |
4.7% |
| Respiratory Failure |
4.7% |
| Septic Shock |
4.7% |
| Acute Graft Versus Host Disease |
3.1% |
| Diarrhoea |
3.1% |
| Drug Effect Decreased |
3.1% |
| Epistaxis |
3.1% |
| Multi-organ Failure |
3.1% |
| Pancytopenia |
3.1% |
| Pneumonia |
3.1% |
| Pneumonia Fungal |
3.1% |
| Pneumonia Viral |
3.1% |
| Product Packaging Issue |
3.1% |
| Pulmonary Alveolar Haemorrhage |
3.1% |
| Pulmonary Embolism |
3.1% |
| Renal Failure |
3.1% |
|
| Interacting |
| Hepatosplenic Candidiasis |
50.0% |
| Hypertension |
50.0% |
|
| Oedema |
50.0% |
| Arrhythmia |
25.0% |
| Sinus Tachycardia |
25.0% |
|
